A Phase 2 Study of WEE1 Inhibition With AZD1775 Alone or Combined With Cytarabine in Patients With Advanced Acute Myeloid Leukemia and Myelodysplastic Syndrome
Phase of Trial: Phase II
Latest Information Update: 05 Dec 2017
At a glance
- Drugs AZD-1775 (Primary) ; Cytarabine
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Biomarker; Therapeutic Use
- 27 Jun 2017 Status changed from not yet recruiting to recruiting.
- 12 Sep 2016 Planned initiation date changed from 1 Apr 2016 to 1 Dec 2016.
- 12 Feb 2016 New trial record